Spotlight Session - BRACE

(B25) A Digital Toolkit to Contextualise and Visualise the Benefit and Risk of COVID-19 Vaccines in the European Union

(B26) Assessment of the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) for Prasugrel (Effient)

(B27) Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy Materials

(B28) Physician Knowledge of Safe Use of Cyproterone Acetate Monotherapies and Meningioma

(B29) The Use of Statins for the Primary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: A Quantitative Benefit-Risk Analysis

(B30) Utility of Healthcare Professional (HCP) Surveys for Evaluating the Effectiveness of Additional Risk Minimization Measures (aRMMs): Experience from an HCP Survey Assessing the Effectiveness of aRMMs for Xeljanz® in Europe

(B31) What are patient with non-small cell lung cancer (NSCLC) preferences regarding treatment?

(B32) What do we know on patient preferences for treatment of multiple sclerosis?